[P62] Poster Session 62　Lung Cancer/Thoracic Cancer（Locally advanced）

[P62-1] Durvalumab for patients with stage III NSCLC and Grade 1 radiation pneumonitis: multicenter prospective cohort study

^○Takashi Yokoi¹, Fujimoto Daichi², Tamiya Motohiro³, Sato Yuki⁴, Taniguchi Yoshihiko⁵, Fukuda Yasushi⁶, Uchida Junji⁷, Hata Akito⁸, Matsumoto Hirotaka⁹, Aoi Hino¹⁰, Kanazu Masaki¹¹, Hara Satoshi¹², Sugimoto Takeya², Kokubo Masaki¹³ (1.Department of Thoracic Oncology, Hyogo College of Medicine, 2.Internal Medicine III, Wakayama Medical University, 3.Department of Thoracic Oncology, Osaka International Cancer Institute, 4.Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 5.Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 6.Department of Respiratory Medicine, Kurashiki Central Hospital, 7.Department of Respiratory Medicine, Osaka General Medical Center, 8.Division of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, 9.Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, 10.Department of Respirology, Chiba University Graduate School of Medicine, 11.Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, 12.Respiratory Division, Department of Internal Medicine, Itami City Hospital, 13.Department of Radiation Oncology, Kobe City Medical Center General Hospital)